| ●Editorial | Kurihara M | 436-7 |
| ●The 30th Aso-Kuju Conference on Clinical Pharmacology Clinical pharmacology：The past, present, and future Chairman：Sasaguri T，Ohashi K，Nomoto M，Ieiri I， Higuchi S，Hasegawa J，Yamada K，Nakano S | 439-501 | |
| Thirty years of Aso-Kuju Conference on Clinical Pharmacology: Past, present and future of clinical pharmacology and therapeutics | Nakano S | 442-50 |
| Clinical trials in clinical pharmacology | Ohashi K | 451-3 |
| Clinical pharmacology for medical treatments | Nomoto M | 454-8 |
| Pharmacology and clinical pharmacology | Sasaguri T | 459-65 |
| Center for Advanced Medical Innovation | Hashizume M | 466-70 |
| Clinical pharmacology education in the faculty of pharmaceutical sciences | Ieiri I | 471-4 |
| Good journal and good article: clinical trial registry and CONSORT statement | Tsutani K | 475-84 |
| Publication ethics and publication bias | Yamazaki S | 485-90 |
| Major database for clinical trials and clinical practice guidelines in Japan | Uchida E | 491-6 |
| Discussion | 497-8 | |
| Scientific session 1, 2 | 499-500 | |
| ●First-in-Human Trial Seminar & Workshop: An MHLW Core Hospital Seminar, supported by MHLW grant for promoting clinical research Organized by：General Clinical Research Center, Oita University Hospital， Clinical Pharmacology Center, Oita University Hospital | 503-46 | |
| Government policies for first-in-human study in Japan | Sato T | 505-10 |
| Impact of exploratory investigational new drug studies in drug development | Tsuji A | 511-8 |
| Non-clinical toxicity study for human initial administration | Onodera H | 519-26 |
| Rheumatoid arthritis (RA) | Kishi J | 527-35 |
| Workshop and plenary discussion | 536-46 | |
| ●CDISC as the global standards | ||
| History, current status and future scope of CDISC as the global standards -Interview with Dr. Kush, the President of CDISC- | Kush RD，Fukushima M，Takenouchi K，et al. | 547-57 |
| CDISC outline and strategic goals | Takenouchi K | 559-61 |
| Global approach to accelerating medical research | Kush RD | 563-88 |
| ●Interview | ||
| Novel strategies of early phase drug development: RapidFACT, iv-Microtracer, and microdosing-Interview with Dr. Lloyd Stevens- ・Full text version in English is here ! | Stevens L （Interview and trans. by Kurihara C，Saio T. Supervised by Inoue T） | 589-600 |
| ●Articles | ||
| Present situations and future of the educational environment for the clinical development in Japan: A study based on a questionnaire survey | Somekawa L，Kurokawa T | 601-11 |
| The importance of personalized drug safety information: Revaluation of
the ADR causal assessment in pharmacovigilance towards good pharmacoepidemiological studies | Suzuki S | 613-36 |
| ●Forum | ||
| Report of “Basic and practical workshop of regulatory affairs for clinical research in academia” supported by the Coordination, Support and Training Program for Translational Research, MEXT | Myoui A，Ando T | 637-40 |
| Neuroethics and the historical overview of psychiatric ethics | Imamura O，Mima T | 641-7 |
| ●Instructions for authors [Japanese] & [English] | 649-57 | |
| ●Editor's note | Gotoh E | 659 |